Barclays’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1
| Closed | – | – | 4673 |
|
|
2025
Q1 | $0 | Buy |
+1
| New | – | ﹤0.01% | 4625 |
|
|
2024
Q2 | – | Sell |
-1,532
| Closed | -$27K | – | 4360 |
|
|
2024
Q1 | $27K | Sell |
1,532
-1,496
| -49% | -$26.4K | ﹤0.01% | 3919 |
|
|
2023
Q4 | $47K | Buy |
3,028
+2,219
| +274% | +$34.4K | ﹤0.01% | 3852 |
|
|
2023
Q3 | $39K | Buy |
809
+2
| +0.2% | +$96 | ﹤0.01% | 3697 |
|
|
2023
Q2 | $63K | Sell |
807
-742
| -48% | -$57.9K | ﹤0.01% | 3581 |
|
|
2023
Q1 | $140K | Buy |
1,549
+323
| +26% | +$29.2K | ﹤0.01% | 3344 |
|
|
2022
Q4 | $144K | Buy |
1,226
+305
| +33% | +$35.8K | ﹤0.01% | 3267 |
|
|
2022
Q3 | $167K | Sell |
921
-2,358
| -72% | -$428K | ﹤0.01% | 3185 |
|
|
2022
Q2 | $294K | Buy |
3,279
+2,435
| +289% | +$218K | ﹤0.01% | 2916 |
|
|
2022
Q1 | $131K | Buy |
+844
| New | +$131K | ﹤0.01% | 3554 |
|